Discovery of a novel small-molecule targeting selective clearance of mutant huntingtin fragments

Journal of Biomolecular Screening

Volumn 12, Issue 3, 2007, Pages 351-360

  Coufal, Myra ^a   Maxwell, Michele M ^b   Russel, Deborah E ^b   Amore, Allison M ^b   Altmann, Stephen M ^b   Hollingsworth, Zane R ^b   Young, Anne B ^a   Housman, David E ^a   Kazantsev, Aleksey G ^b  

^a MASSACHUSETTS INSTITUTE OF TECHNOLOGY   (United States)

^b MASSACHUSETTS GENERAL HOSPITAL   (United States)

Author keywords

High throughput screening; Huntingtin; Huntington's disease; Protein clearance; Toxicity rescue

Indexed keywords

A 28; A 31; BETA GALACTOSIDASE; CYSTAMINE; GREEN FLUORESCENT PROTEIN; HUNTINGTIN; MUTANT PROTEIN; NEUROPROTECTIVE AGENT; POLYGLUTAMINE; POLYPEPTIDE; UNCLASSIFIED DRUG;

ANIMAL CELL; ARTICLE; CELL VIABILITY; CLEARANCE; CONCENTRATION RESPONSE; CYTOTOXICITY; DRUG MECHANISM; DRUG TARGETING; ENZYME ASSAY; FUNCTIONAL ASSESSMENT; HIGH THROUGHPUT SCREENING; NONHUMAN; NUCLEOTIDE REPEAT; PATHOLOGY; PRIORITY JOURNAL; PROTEIN TARGETING; RAT; REPORTER GENE; VALIDATION PROCESS;

ANIMALS; DOSE-RESPONSE RELATIONSHIP, DRUG; DRUG EVALUATION, PRECLINICAL; GREEN FLUORESCENT PROTEINS; MOLECULAR WEIGHT; MUTANT PROTEINS; NERVE TISSUE PROTEINS; PC12 CELLS; PEPTIDE FRAGMENTS; PEPTIDES; RATS; REPRODUCIBILITY OF RESULTS; SENSITIVITY AND SPECIFICITY; SUBSTRATE SPECIFICITY;

EID: 34047170795     PISSN: 10870571     EISSN: 1552454X     Source Type: Journal    
DOI: 10.1177/1087057107299428     Document Type: Article

References (25)

1. Bates G, Harper PS, Jones L, eds.: Huntington's Disease. 3 rd ed. Oxford, UK: Oxford University Press, 2002.
2. Cattaneo E., Zuccato C., Tartari M.: Normal huntingtin function: an alternative approach to Huntington's disease. Nat Rev Neurosci 2005 ; 6: 919-930.
3. Duyao MP, Auerbach AB, Ryan A., Persichetti F., Barnes GT, McNeil SM,, et al. Inactivation of the mouse Huntington's disease gene homolog Hdh. Science 1995 ; 269: 407-410.
4. Nasir J., Floresco SB, O'Kusky JR, Diewert VM, Richman JM, Zeisler J.,, et al. Targeted disruption of the Huntington's disease gene results in embryonic lethality and behavioral and morphological changes in heterozygotes. Cell 1995 ; 81: 811-823.
5. Zeitlin S., Liu JP, Chapman DL, Papaioannou VE, Efstratiadis A.: Increased apoptosis and early embryonic lethality in mice nullizygous for the Huntington's disease gene homologue. Nat Genet 1995 ; 11: 155-163.
6. Dragatsis I., Levine MS, Zeitlin S.: Inactivation of Hdh in the brain and testis results in progressive neurodegeneration and sterility in mice. Nat Genet 2000 ; 26: 300-306.
7. Rigamonti D., Bauer JH, De-Fraja C., Conti L., Sipione S., Sciorati C.,, et al. Wild-type huntingtin protects from apoptosis upstream of caspase-3. J Neurosci 2000 ; 20: 3705-3713.
8. Ho LW, Brown R., Maxwell M., Wyttenbach A., Rubinsztein DC: Wild type Huntingtin reduces the cellular toxicity of mutant Huntingtin in mammalian cell models of Huntington's disease. J Med Genet 2001 ; 38: 450-452.
9. Hackam AS, Singaraja R., Wellington CL, Metzler M., McCutcheon K., Zhang T.,, et al. The influence of huntingtin protein size on nuclear localization and cellular toxicity. J Cell Biol 1998 ; 141: 1097-1105.
10. Strong TV, Tagle DA, Valdes JM, Elmer LW, Boehm K., Swaroop M.,, et al. Widespread expression of the human and rat Huntington's disease gene in brain and nonneural tissues. Nat Genet 1993 ; 5: 259-265.
11. DiFiglia M., Sapp E., Chase K., Schwarz C., Meloni A., Young C.,, et al. Huntingtin is a cytoplasmic protein associated with vesicles in human and rat brain neurons. Neuron 1995 ; 14: 1075-1081.
12. Persichetti F., Srinidhi J., Kanaley L., Ge P., Myers RH, D'Arrigo K.,, et al. Huntington's disease CAG trinucleotide repeats in pathologically confirmed post mortem brains. Neurobiol Dis 1994 ; 1: 159-166.
13. Halliday GM, McRitchie DA, Macdonald V., Double KL, Trent RJ, McCusker E.: Regional specificity of brain atrophy in Huntington's disease. Exp Neurol 1998 ; 154: 663-672.
14. Ross CA, Poirier MA: Protein aggregation and neurodegenerative disease. Nat Med 2004 ; 10 (Suppl): S10 - S17.
15. Chen S., Ferrone FA, Wetzel R.: Huntington's disease age-of-onset linked to polyglutamine aggregation nucleation. Proc Natl Acad Sci USA 2002 ; 99: 11884-11889.
16. Yamamoto A., Lucas JJ, Hen R.: Reversal of neuropathology and motor dysfunction in a conditional model of Huntington's disease. Cell 2000 ; 101: 57-66.
17. Diaz-Hernandez M., Hernandez F., Martin-Aparicio E., Gomez-Ramos P., Moran MA, Castano JG,, et al. Neuronal induction of the immunoproteasome in Huntington's disease. J Neurosci 2003 ; 23: 11653-11661.
18. Diaz-Hernandez M., Moreno-Herrero F., Gomez-Ramos P., Moran MA, Ferrer I., Baro AM,, et al. Biochemical, ultrastructural, and reversibility studies on huntingtin filaments isolated from mouse and human brain. J Neurosci 2004 ; 24: 9361-9371.
19. Diaz-Hernandez M., Torres-Peraza J., Salvatori-Abarca A., Moran MA, Gomez-Ramos P., Alberch J.,, et al. Full motor recovery despite striatal neuron loss and formation of irreversible amyloid-like inclusions in a conditional mouse model of Huntington's disease. J Neurosci 2005 ; 25: 9773-9781.
20. Apostol BL, Kazantsev A., Raffioni S., Illes K., Pallos J., Bodai L.,, et al. A cell-based assay for aggregation inhibitors as therapeutics of polyglutamine-repeat disease and validation in Drosophila. Proc Natl Acad Sci USA 2003 ; 100: 5950-5955.
21. Aiken CT, Tobin AJ, Schweitzer ES: A cell-based screen for drugs to treat Huntington's disease. Neurobiol Dis 2004 ; 16: 546-555.
22. Fox JH, Barber DS, Singh B., Zucker B., Swindell MK, Norflus F.,, et al. Cystamine increases L-cysteine levels in Huntington's disease transgenic mouse brain and in a PC12 model of polyglutamine aggregation. J Neurochem 2004 ; 91: 413-422.
23. Harper SQ, Staber PD, He X., Eliason SL, Martins IH, Mao Q.,, et al. RNA interference improves motor and neuropathological abnormalities in a Huntington's disease mouse model. Proc Natl Acad Sci USA 2005 ; 102: 5820-5825.
24. Wang YL, Liu W., Wada E., Murata M., Wada K., Kanazawa I.: Clinicopathological rescue of a model mouse of Huntington's disease by siRNA. Neurosci Res 2005 ; 53: 241-249.
25. Rodriguez-Lebron E., Denovan-Wright EM, Nash K., Lewin AS, Mandel RJ: Intrastriatal rAAV-mediated delivery of antihuntingtin shRNAs induces partial reversal of disease progression in R6/1 Huntington 's disease transgenic mice. Mol Ther 2005 ; 12: 618-633.